ArticleProceedings of the National Academy of Sciences of the United States of America2021
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02320656 (Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015), which is not on this map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- Could the Immune Modulation of Invariant Natural Killer T Cell and the Expression of CD244 and CD196 on Natural Killer Cell Subtypes Impact the Treatment Outcomes of Acute Myeloid Leukemia Patients?Journal of hematology · 2026Article
- EBV Type 1 versus Type 2: A determinant of NK cell anti-tumor activity in Burkitt lymphoma.bioRxiv : the preprint server for biology · 2026Article
- Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.Molecular cancer therapeutics · 2026Article
- HIV-driven tumor ecosystem: from chronic immune dysfunction to cancer evolution.Frontiers in microbiology · 2026Review
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.Journal of translational medicine · 2025Review
- CyTOF as a suitable tool for stratification and monitoring of cancer patients.Journal of translational medicine · 2025Review
- NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Aging and disease · 2025Review
- The diversity of natural killer cell functional and phenotypic states in cancer.Cancer metastasis reviews · 2025Review
- The diversity of natural killer cell functional and phenotypic states in cancer.Cancer metastasis reviews · 2025Review
- Natural killer cells occupy unique spatial neighborhoods in HER2Breast cancer research : BCR · 2025Article
- Polymorphisms in immunosuppression-related genes are associated with AML.Frontiers in immunology · 2025Article
- The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.Frontiers in immunology · 2025Article
- Immediate variations in high-dimensional circulating immune cells following pancreatectomy.Clinical & translational immunology · 2025Article
- The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response.Frontiers in immunology · 2025Review
- NK cell-based immunotherapy strategies for myeloid leukemia.Frontiers in immunology · 2025Review
- Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling.iScience · 2024Article
- Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia.Blood advances · 2024Article
- Current development of Fc gamma receptors (FcγRs) in diagnostics: a review.Molecular biology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 2 institutions in 1 country.
Anne-Sophie ChretienTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France; anne-sophie.chretien@inserm.fr.ORCID 0000-0003-4685-5568
Raynier DevillierTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Samuel GranjeaudSystems Biology Platform, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0001-9245-1535
Charlotte CordierTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Clemence DemerleTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Nassim SalemTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Julia WlosikTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Florence OrlanducciTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Laurent GorvelTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Stephane FattoriTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Marie-Anne HospitalHematology Department, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Jihane PakradouniDepartment of Clinical Research and Innovation, Institut Paoli-Calmettes, 13009 Marseille, France.
Emilie GregoriCentre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille University UMS3367, Inserm US012, CNRS UMS3367, 13009 Marseille, France.
Magali PaulTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Philippe RochigneuxTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0001-7932-0530
Thomas PagliardiniTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Mathieu MoreyR&D department, Datactivist, 13100 Aix-en-Provence, France.
Cyril FauriatTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0002-4850-6831
Nicolas DulphyUniversité de Paris, Institut de Recherche Saint Louis, Inserm U1160, F-75010 Paris, France.ORCID 0000-0002-1243-6456
Antoine ToubertUniversité de Paris, Institut de Recherche Saint Louis, Inserm U1160, F-75010 Paris, France.ORCID 0000-0002-7308-7317
Herve LucheCentre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille University UMS3367, Inserm US012, CNRS UMS3367, 13009 Marseille, France.
Marie MalissenCentre d'Immunophénomique - CIPHE (PHENOMIN), Aix Marseille University UMS3367, Inserm US012, CNRS UMS3367, 13009 Marseille, France.
Didier BlaiseTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0002-5684-9447
Jacques A NunèsTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0003-4865-0400
Norbert VeyHematology Department, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.
Daniel OliveTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University UM105, 13009 Marseille, France.ORCID 0000-0003-1299-4113
Centre National de la Recherche Scientifique · FRInserm · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are major antileukemic immune effectors. Leukemic blasts have a negative impact on NK cell function and promote the emergence of phenotypically and functionally impaired NK cells. In the current work, we highlight an accumulation of CD56
Indexed as
Antigens, CDFlow CytometryHumansImmunophenotypingKiller Cells, NaturalLeukemia, Myeloid, AcuteLymphocyte ActivationRemission InductionTreatment OutcomeAntigens, CDAMLCD56−CD16+ NK cellsmass cytometrynatural killer cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT02320656ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.